IMLFF News and Press, InMed Pharmaceuticals Inc. From 07/07/20

InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755 Canada NewsWire VANCOUVER, BC, July 7, 2020 TSX:IN OTCQX:IMLFF VANCOUVER, BC , July 7, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage ...

Trading of Consolidated Shares on TSX Expected to Begin on July 3 rd , 2020 VANCOUVER, BC , June 30, 2020 /PRNewswire/ -   InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN) (OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting ...

VANCOUVER, BC , June 24, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of ...

VANCOUVER, BC , June 19, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical devel...

VANCOUVER , May 27, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of can...

VANCOUVER , May 19, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of can...

InMed Pharmaceuticals Inc. (IMLFF) Q3 2020 Earnings Conference Call May 14, 2020 11:30 AM ET Company Participants Brendan Payne – Director-Investor Relations Eric Adams – President and Chief Executive Officer Bruce Colwill – Chief Financial Officer Alexandr...

The following slide deck was published by InMed Pharmaceuticals Inc. in conjunction with their 2020 Q3 earnings Read more ...

InMed Pharmaceuticals ( OTCQX:IMLFF ): Q3 GAAP EPS of -C$0.02. Cash, cash equivalents and short-term investments were of C$9.4M. Press Release More news on: InMed Pharmaceuticals Inc., Earnings news and commentary, Tech stocks news, ,

VANCOUVER , May 14, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of c...